Abstract
The outcome of chronic myeloid leukemia (CML) patients improved in the last decade. Clinical prognostic scoring systems aim to provide information about survival in the long-term, without determining from baseline the subset of patients who require a strictly monitoring because at increased risk of failure. Imatinib, the first-generation tyrosine kinase inhibitor (TKI), is still widely used as frontline treatment: recently, the imatinib therapy failure (IMTF) score was proposed to identify the failure free survival. Aim of our study was to validate this index in a large cohort of patients treated with imatinib.
Authors’ contributions
CI, MB wrote the paper; ES, IC, MLB followed the patients; SP performed statistical analysis; MM approved the final version of the paper.
Disclosure statement
MB received honoraria by Novartis, BMS/Celgene, Pfizer, Incyte. All the other authors have no conflict of interests.